DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.
| Cas No.: | 51146-57-7 |
| Chemical Name: | (R)-(-)-Ibuprofen |
| Synonyms: | Benzeneacetic acid, a-methyl-4-(2-methylpropyl)-, (aR)-;(R)-(-)-Ibuprofen;(alphaR)-alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid;L-Ibuprofen;R-(-)-p-Isobutylhydratropic acid;R(-)-ibuprofen;CHEBI:47835;alphaR-Sethyl-4-(2-methylpropyl)benzeneacetic acid;(2R)-2-(4-isobutylphenyl)-propanoic acid;(2R)-2-(4-isobutylphenyl)propanoic acid;(-)-Ibuprofen;R-Ibuprofen;(R)-Ibuprofen;(R)-Ibuprofen |
| SMILES: | C[C@@H](C(=O)O)C1C=CC(CC(C)C)=CC=1 |
| Formula: | C13H18O2 |
| M.Wt: | 206.280824184418 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | (R)-(-)-Ibuprofen is the R enantiomer of Ibuprofen, inactive on COX, inhibits NF-κB activation; (R)-(-)-Ibuprofen exhibits anti-inflammatory and antinociceptive effects. |
| Target: | NF-κB |
| In Vitro: | (R)-(-)-Ibuprofen is the R enantiomer of Ibuprofen, with no inhibitory effect on COX, but is involved in pathways of lipid metabolism and is incorporated into triglycerides along with endogenous fatty acids[1]. (R)-(-)-Ibuprofen (1 μM) significantly reduces NF-κB activation and completely prevents NF-κB induction at 10 μM. (R)-(-)-Ibuprofen inhibits NF-κB luciferase activity with an IC50 of 121.8 μM, weaker than that of S(+)-ibuprofen (IC50, 61.7 μM). Furthermore, (R)-(-)-Ibuprofen (10 mM) has no effect on HSF[2]. |
| References: | [1]. Evans AM, et al. Comparative pharmacology of S(+)-ibuprofen and (RS)-ibuprofen. Clin Rheumatol. 2001 Nov;20 Suppl 1:S9-14. [2]. Scheuren N, et al. Modulation of transcription factor NF-kappaB by enantiomers of the nonsteroidal drug ibuprofen. Br J Pharmacol. 1998 Feb;123(4):645-52. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|
| 2018-0101 |
|